JP2002512978A - ニコチン含有溶液 - Google Patents
ニコチン含有溶液Info
- Publication number
- JP2002512978A JP2002512978A JP2000545568A JP2000545568A JP2002512978A JP 2002512978 A JP2002512978 A JP 2002512978A JP 2000545568 A JP2000545568 A JP 2000545568A JP 2000545568 A JP2000545568 A JP 2000545568A JP 2002512978 A JP2002512978 A JP 2002512978A
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- solution
- human
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 385
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 384
- 229960002715 nicotine Drugs 0.000 title claims abstract description 384
- 239000000243 solution Substances 0.000 claims abstract description 180
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000000391 smoking effect Effects 0.000 claims abstract description 40
- 208000024891 symptom Diseases 0.000 claims abstract description 35
- 241000282412 Homo Species 0.000 claims abstract description 25
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 21
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 21
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 20
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 20
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims abstract description 20
- 230000035622 drinking Effects 0.000 claims abstract description 18
- 239000003929 acidic solution Substances 0.000 claims abstract 4
- 230000036765 blood level Effects 0.000 claims description 31
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 26
- 230000004060 metabolic process Effects 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 20
- 235000019634 flavors Nutrition 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 13
- 210000003240 portal vein Anatomy 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 235000016213 coffee Nutrition 0.000 claims description 11
- 235000013353 coffee beverage Nutrition 0.000 claims description 11
- 235000015203 fruit juice Nutrition 0.000 claims description 11
- 235000013405 beer Nutrition 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 230000009747 swallowing Effects 0.000 claims description 10
- 235000015041 whisky Nutrition 0.000 claims description 10
- 235000014101 wine Nutrition 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 9
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 210000000214 mouth Anatomy 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 230000005945 translocation Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 210000001198 duodenum Anatomy 0.000 claims description 5
- 210000003238 esophagus Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 abstract description 16
- 239000000779 smoke Substances 0.000 abstract description 7
- 235000013361 beverage Nutrition 0.000 description 18
- 235000019504 cigarettes Nutrition 0.000 description 11
- 230000005586 smoking cessation Effects 0.000 description 11
- 244000061176 Nicotiana tabacum Species 0.000 description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019505 tobacco product Nutrition 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000020140 chocolate milk drink Nutrition 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940015769 nicotine chewing gum Drugs 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 235000021572 root beer Nutrition 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229940124535 smoking cessation aid Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000014080 ginger ale Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940061254 nicotine 1 mg Drugs 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/070,263 US6211194B1 (en) | 1998-04-30 | 1998-04-30 | Solution containing nicotine |
| US09/070,263 | 1998-04-30 | ||
| PCT/US1999/008752 WO1999055371A1 (en) | 1998-04-30 | 1999-04-21 | Solution containing nicotine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002512978A true JP2002512978A (ja) | 2002-05-08 |
| JP2002512978A5 JP2002512978A5 (enExample) | 2006-06-15 |
Family
ID=22094213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545568A Pending JP2002512978A (ja) | 1998-04-30 | 1999-04-21 | ニコチン含有溶液 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6211194B1 (enExample) |
| EP (1) | EP1073466A4 (enExample) |
| JP (1) | JP2002512978A (enExample) |
| AU (1) | AU745292B2 (enExample) |
| CA (1) | CA2330644A1 (enExample) |
| NZ (1) | NZ507845A (enExample) |
| WO (1) | WO1999055371A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006511566A (ja) * | 2002-12-20 | 2006-04-06 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| JP2008528028A (ja) * | 2005-01-27 | 2008-07-31 | マーシャル アンラーフ トンプソン | ニコチン組成物の製造方法 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268386B1 (en) * | 1998-06-25 | 2001-07-31 | Marshall Anlauf Thompson | Nicotine beverage |
| US6358060B2 (en) * | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
| US20020098264A1 (en) * | 1998-11-27 | 2002-07-25 | Cherukuri Subraman R. | Medicated chewing gum delivery system for nicotine |
| JP2004512907A (ja) * | 2000-11-03 | 2004-04-30 | リカバリー ファーマシューティカルズ インコーポレーティッド | 禁煙用の装置および方法 |
| US20050131031A1 (en) * | 2001-12-10 | 2005-06-16 | Thompson Marshall A. | Method of producing a nicotine composition |
| US20030108592A1 (en) * | 2001-12-10 | 2003-06-12 | Thompson Marshall Anlauf | Method of producing a nicotine composition |
| US20060204598A1 (en) * | 2001-12-10 | 2006-09-14 | Thompson Marshall A | Nicotine-alternative compositions and methods of producing such compositions |
| US20060105023A1 (en) * | 2001-12-10 | 2006-05-18 | Knight Joseph R | Treatment of neurological disorders with nicotine |
| EP1461037B1 (en) * | 2001-12-10 | 2007-08-01 | Joseph Robert Knight | Process for preparation of a beverage treated with a nicotine containing substance |
| US20100160376A1 (en) * | 2001-12-10 | 2010-06-24 | Marshall Anlauf Thompson | Nicotine-alternative compositions and methods of producing such compositions |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| US7767698B2 (en) * | 2002-06-03 | 2010-08-03 | Mcneil Ab | Formulation and use thereof |
| US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
| CN104397869B (zh) | 2003-11-07 | 2016-06-08 | 美国无烟烟草有限责任公司 | 烟草组合物 |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US7766018B2 (en) | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
| US8642016B2 (en) * | 2006-07-21 | 2014-02-04 | Jsrnti, Llc | Medicinal delivery system, and related methods |
| AU2006348180A1 (en) * | 2006-09-13 | 2008-03-20 | Warner Chilcott Company, Llc | Methods of treatment for ulcerative colitis |
| US20100048519A1 (en) * | 2006-09-13 | 2010-02-25 | Chyon-Hwa Yeh | Methods of treatment for ulcerative colitis using aminosalicylate |
| ES2521494T3 (es) * | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| EP2706854A4 (en) * | 2011-05-09 | 2014-12-03 | Envivo Pharmaceuticals Inc | TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| KR102705152B1 (ko) | 2013-05-06 | 2024-09-09 | 쥴 랩스, 인크. | 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법 |
| KR102957402B1 (ko) | 2013-12-05 | 2026-04-24 | 쥴 랩스, 인크. | 에어로졸 장치를 위한 니코틴 액제 및 그 방법 |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US20210255202A1 (en) | 2018-06-13 | 2021-08-19 | Michael R. D'Andrea | Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment |
| EP3807260B1 (en) | 2018-06-15 | 2024-09-18 | R. J. Reynolds Tobacco Company | Purification of nicotine |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| BR102020002169A2 (pt) * | 2020-01-31 | 2021-08-10 | Bruno Ghizoni Da Silva Comércio De Produtos E Serviços Inovadores-Me | Bebida estimulante |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870794A (en) * | 1974-02-20 | 1975-03-11 | Foundation For Behavioral Rese | Treatment of certain emotional disorders with nicotine compounds |
| JPH02501304A (ja) * | 1986-11-18 | 1990-05-10 | フォルシュングゲゼルシャフト・ラウヘン・ウント・ゲスンドハイト・エムベーハー | ニコチン含有流動媒質を含む口経投与用カプセル |
| JPH02180832A (ja) * | 1988-10-28 | 1990-07-13 | Warner Lambert Co | 食用アニオン交換樹脂デリバリーシステムを調製する方法 |
| JPH0391434A (ja) * | 1988-06-13 | 1991-04-17 | Basf K & F Corp | コレスチルアミンを含有する食用の焼いた組成物 |
| JPH0795867A (ja) * | 1993-09-28 | 1995-04-11 | Takeda Chem Ind Ltd | 飲用液組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR899037A (fr) | 1942-06-17 | 1945-05-15 | Metallguss & Presswerk H Diehl | Alliage de zinc ductile |
| GB2142822B (en) | 1983-06-29 | 1987-02-11 | Alec Stanley Walter Shaw | Nicotine lozenges |
| GB8317576D0 (en) | 1983-06-29 | 1983-08-03 | Shaw A S W | Consumer tobacco products |
| EP0395683A4 (en) * | 1987-11-19 | 1991-01-30 | Indaus International Pty Ltd | Nicotine compositions |
| SE8904295D0 (sv) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Smoking substitute |
| US5147654A (en) * | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
| US5135753A (en) * | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5780051A (en) * | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
| US5596007A (en) * | 1992-05-18 | 1997-01-21 | Pharmaco Behavioral Associates, Inc. | Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine |
| US5383478A (en) | 1993-01-12 | 1995-01-24 | Duke University | Low tar and low nicotine cigarette adapted to provide enhanced smoking satisfaction |
| IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| CN1089834A (zh) * | 1993-10-14 | 1994-07-27 | 王子芸 | 戒烟口胶的配方及加工工艺 |
| US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
-
1998
- 1998-04-30 US US09/070,263 patent/US6211194B1/en not_active Expired - Lifetime
-
1999
- 1999-04-21 WO PCT/US1999/008752 patent/WO1999055371A1/en not_active Ceased
- 1999-04-21 CA CA002330644A patent/CA2330644A1/en not_active Abandoned
- 1999-04-21 EP EP99919947A patent/EP1073466A4/en not_active Ceased
- 1999-04-21 JP JP2000545568A patent/JP2002512978A/ja active Pending
- 1999-04-21 AU AU37547/99A patent/AU745292B2/en not_active Ceased
- 1999-04-21 NZ NZ507845A patent/NZ507845A/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870794A (en) * | 1974-02-20 | 1975-03-11 | Foundation For Behavioral Rese | Treatment of certain emotional disorders with nicotine compounds |
| JPH02501304A (ja) * | 1986-11-18 | 1990-05-10 | フォルシュングゲゼルシャフト・ラウヘン・ウント・ゲスンドハイト・エムベーハー | ニコチン含有流動媒質を含む口経投与用カプセル |
| JPH0391434A (ja) * | 1988-06-13 | 1991-04-17 | Basf K & F Corp | コレスチルアミンを含有する食用の焼いた組成物 |
| JPH02180832A (ja) * | 1988-10-28 | 1990-07-13 | Warner Lambert Co | 食用アニオン交換樹脂デリバリーシステムを調製する方法 |
| JPH0795867A (ja) * | 1993-09-28 | 1995-04-11 | Takeda Chem Ind Ltd | 飲用液組成物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006511566A (ja) * | 2002-12-20 | 2006-04-06 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| JP2008528028A (ja) * | 2005-01-27 | 2008-07-31 | マーシャル アンラーフ トンプソン | ニコチン組成物の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2330644A1 (en) | 1999-11-04 |
| AU745292B2 (en) | 2002-03-21 |
| WO1999055371A1 (en) | 1999-11-04 |
| US6211194B1 (en) | 2001-04-03 |
| EP1073466A1 (en) | 2001-02-07 |
| EP1073466A4 (en) | 2001-08-16 |
| AU3754799A (en) | 1999-11-16 |
| NZ507845A (en) | 2003-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU745292B2 (en) | Solution containing nicotine | |
| Wadgave et al. | Nicotine replacement therapy: an overview | |
| RU2279871C2 (ru) | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта | |
| WO2021003467A1 (en) | Metered dosing compositions and methods of use of psychedelic compounds | |
| CN102770138B (zh) | 含有尼古丁的软凝胶锭剂 | |
| JP2002512978A5 (enExample) | ||
| HUT74920A (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
| HUE035266T2 (en) | As a buffer, a pharmaceutical product containing trometamol for oral administration of nicotine | |
| AU2002224525B2 (en) | Compositions for regulating desire for smoking | |
| JPH0432802B2 (enExample) | ||
| JP2004512907A (ja) | 禁煙用の装置および方法 | |
| AU2010360967A1 (en) | Nicotine containing formulation | |
| US20030008005A1 (en) | Sublingual administration of dihydroergotamine for the treatment of migraine | |
| US20100113453A1 (en) | Sublingual Formulations of D-Cycloserine and Methods of Using Same | |
| RU2445971C2 (ru) | Водный экстракт листьев табака и его применение при лечении зависимости | |
| Prignot | Pharmacological approach to smoking cessation | |
| US10610483B2 (en) | Vaporized medicants and methods of use | |
| Corelli et al. | Pharmacologic interventions for smoking cessation | |
| MXPA00010494A (en) | Solution containing nicotine | |
| RU2120280C1 (ru) | Гомеопатическое средство "аценамет" для осуществления способа лечения алкогольной зависимости | |
| TWI905885B (zh) | β–石竹烯之用途 | |
| US20150328202A1 (en) | Edible product for nicotine delivery | |
| Chauhan et al. | Nicotine replacement therapy for smoking cessation | |
| WO2025246685A1 (zh) | 一种上头感组合物、液体制剂、尼古丁液体制剂及其制备方法和应用 | |
| Whittaker | Nicotine replacement therapy: medicine cupboard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060420 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070220 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20070220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100224 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100303 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100323 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101207 |